A case by Remon et al. utilized IV atezolizumab, a PDL-1 inhibitor, in combination with bevacizumab and paclitaxel in the treatment of a 73-year-old man with NSCLC and progressive intraparenchymal metastasis and LMD. This evidence concerns the gene CD274 and non-small cell lung carcinoma.